Olivia Sottile
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Olivia Sottile has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Abby Dorsky
Department of Physics and Astronomy, Texas Christian University, Fort Worth, TX 76129, USA
1 shared publication - Adam Bhaloo
Department of Physics and Astronomy, Texas Christian University, Fort Worth, TX 76129, USA
1 shared publication - Alina Valimukhametova
Texas Christian University
1 shared publication - Anton V. Naumov
Department of Physics and Astronomy Texas Christian University TCU Box 298840 Fort Worth TX 76129 USA
1 shared publication - Bong Lee
Department of Physics and Astronomy, Texas Christian University, Fort Worth, TX 76129, USA
1 shared publication - Roberto Gonzalez-Rodriguez
Department of Physics, University of North Texas 1 , Denton, Texas 76203
1 shared publication
Latest Publications
- Open Access
- 31 July 2023
- Published by MDPI AG in Antioxidants
- Vol. 12 (8) , 1536
Doped Graphene Quantum Dots as Biocompatible Radical Scavenging Agents
Oxidative stress is proven to be a leading factor in a multitude of adverse conditions, from Alzheimer’s disease to cancer. Thus, developing effective radical scavenging agents to eliminate reactive oxygen species (ROS) driving many oxidative processes has become critical. In addition to conventional antioxidants, nanoscale structures and metal–organic complexes have recently shown promising potential for radical scavenging. To design an optimal nanoscale ROS scavenging agent, we have synthesized ten types of biocompatible graphene quantum dots (GQDs) augmented with various metal dopants. The radical scavenging abilities of these novel metal-doped GQD structures were, for the first time, assessed via the DPPH, KMnO4, and RHB (Rhodamine B protectant) assays. While all metal-doped GQDs consistently demonstrate antioxidant properties higher than the undoped cores, aluminum-doped GQDs exhibit 60–95% radical scavenging ability of ascorbic acid positive control. Tm-doped GQDs match the radical scavenging properties of ascorbic acid in the KMnO4 assay. All doped GQD structures possess fluorescence imaging capabilities that enable their tracking in vitro, ensuring their successful cellular internalization. Given such multifunctionality, biocompatible doped GQD antioxidants can become prospective candidates for multimodal therapeutics, including the reduction of ROS with concomitant imaging and therapeutic delivery to cancer tumors.
- 31 July 2023
- Published by MDPI AG in Antioxidants
- Vol. 12 (8) , 1536
Open AccessDoped Graphene Quantum Dots as Biocompatible Radical Scavenging Agents
Oxidative stress is proven to be a leading factor in a multitude of adverse conditions, from Alzheimer’s disease to cancer. Thus, developing effective radical scavenging agents to eliminate reactive oxygen species (ROS) driving many oxidative processes has become critical. In addition to conventional antioxidants, nanoscale structures and metal–organic complexes have recently shown promising potential for radical scavenging. To design an optimal nanoscale ROS scavenging agent, we have synthesized ten types of biocompatible graphene quantum dots (GQDs) augmented with various metal dopants. The radical scavenging abilities of these novel metal-doped GQD structures were, for the first time, assessed via the DPPH, KMnO4, and RHB (Rhodamine B protectant) assays. While all metal-doped GQDs consistently demonstrate antioxidant properties higher than the undoped cores, aluminum-doped GQDs exhibit 60–95% radical scavenging ability of ascorbic acid positive control. Tm-doped GQDs match the radical scavenging properties of ascorbic acid in the KMnO4 assay. All doped GQD structures possess fluorescence imaging capabilities that enable their tracking in vitro, ensuring their successful cellular internalization. Given such multifunctionality, biocompatible doped GQD antioxidants can become prospective candidates for multimodal therapeutics, including the reduction of ROS with concomitant imaging and therapeutic delivery to cancer tumors.